Erik van den Berg, Memo Therapeutics CEO

Memo Ther­a­peu­tics re­fu­els with $22M to ex­pand tri­al for in­fec­tion-fight­ing an­ti­body in kid­ney trans­plant re­cip­i­ents

Swiss biotech Memo Ther­a­peu­tics raised $22 mil­lion (CHF 20 mil­lion) in a Se­ries C ex­ten­sion to de­vel­op an an­ti­body treat­ment for BK poly­omavirus (BKV) in­fec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.